

1 **A Systematic Review on the Effect of Diabetes Mellitus on the Pharmacokinetics of**
2 **Tuberculosis Drugs**

3

4

5 **Authors:** Muge Cevik^{1*}, Ann Sturdy², Alberto Enrico Maraolo³, Bart G.J. Dekkers⁴, Onno
6 W. Akkerman^{5,6}, Stephen H. Gillespie¹, Jan Willem C. Alffenaar⁷⁻⁹

7

8

9 **Affiliations:**

10 1. Division of Infection and Global Health Research, School of Medicine, University of St
11 Andrews, UK

12 2. Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK

13 3. Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University
14 of Naples 'Federico II', Italy

15 4. University of Groningen, University Medical Center Groningen, Department of Clinical
16 Pharmacy and Pharmacology, Groningen, the Netherlands

17 5. University of Groningen, University Medical Center Groningen, Department of
18 Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands

19 6. University of Groningen, University Medical Center Groningen, Tuberculosis Center
20 Beatrixoord, Haren, the Netherlands

21 7. The University of Sydney Institute for Infectious Diseases, Sydney, NSW, Australia.

22 8. School of Pharmacy, Faculty of Medicine and Health, The University of Sydney,
23 Sydney, NSW, Australia.

24 9. Westmead Hospital, Westmead, NSW, Australia

25

26 **Running head : Pharmacokinetics of TB Drugs in DM**

27

28 ***Corresponding author:**

29 Dr Muge Cevik

30 Division of Infection and Global Health Research,

31 School of Medicine, University of St Andrews, Fife, KY16 9TF

32 Telephone number: +447732800814

33 Email address: mc349@st-andrews.ac.uk

34

35

36 **Abstract**

37

38 **Objectives**

39 The coexistence of TB and DM (TB-DM) has been associated with an increased risk of
40 treatment failure, death, delayed culture conversion and drug resistance. As plasma
41 concentrations may influence clinical outcomes, we evaluated the evidence on the PK of
42 TB drugs in DM individuals to guide management.

43

44 **Methods**

45 We performed a systematic review and meta-analysis through searches of major
46 databases from 1946 to 6 July 2023. PROSPERO (CRD42022323566).

47

48 **Results**

49 Out of 4173 potentially relevant articles, we identified 16 studies assessing rifampicin PK,
50 9 on isoniazid, 8 on pyrazinamide and 3 on ethambutol. Two studies reported on second
51 line anti-TB drugs. According to our analysis, RIF T_{max} was significantly prolonged in
52 patients with DM compared to non-DM patients. We found no significant differences for
53 RIF C_{max}, AUC₀₋₂₄ or C_{2hr}, INH C_{2hr}, PZA C_{2hr}, PZA T_{max} and ETB T_{max}. While RIF C_{2hr}
54 was slightly reduced in TB-DM patients, this finding was not statistically significant.

55

56 **Conclusions**

57 This review comprehensively examines the impact of DM on the PK of TB drugs. We
58 observed significant heterogeneity among studies. Given the association between lower
59 plasma concentrations and poor clinical outcomes among DM patients, we recommend a
60 higher dose limit to correct for larger bodyweight of patients with DM.

61 INTRODUCTION

62

63 The global tuberculosis (TB) burden remains substantial, with more than 10 million people
64 newly diagnosed per year.¹ Non-communicable diseases continue to pose challenges for
65 both the management of TB and control strategies. For instance, over the next 10 years,
66 the prevalence of Diabetes mellitus (DM) is estimated to double globally, with TB and DM
67 co-epidemic surpassing the TB-HIV coinfection in low-middle income countries.^{2,3} More
68 alarmingly DM is increasing in the same population that is at high risk for developing TB.

69

70 DM is specifically important for the TB epidemic and future policies as DM has been
71 shown to double the risk of acquiring TB^{4,5} and DM patients have three-fold increased risk
72 of progression to active disease,⁵ highlighting that increased prevalence of DM will help to
73 maintain the TB epidemic. In addition, TB-DM patients experience increased risk of severe
74 disease, treatment failure, relapse and increased risk of death^{6,7} as well as delayed
75 sputum culture conversion and a greater risk of developing drug resistance.^{8,9}

76

77 There is however limited practical evidence to underpin treatment guidelines for TB-DM
78 patients, such as length of treatment and drug dosing. This is important as plasma
79 concentrations of TB medications may affect the clinical outcome. Zheng et al¹⁰ showed
80 an association between plasma concentrations of first line anti-TB drugs, culture
81 conversion and clinical outcomes. Alfarisi et al.¹¹ demonstrated a positive association
82 between time to culture conversion and isoniazid (INH) and rifampicin (RIF) concentrations
83 and negative association with pyrazinamide (PZA) levels in DM patients. Pharmacokinetics
84 (PK) of many other drugs are known to be altered in diabetic individuals.¹² DM may affect
85 kidney function, gastric emptying and drug metabolism pathways.¹² This highlights the
86 importance of understanding PK in TB-DM population.¹³

87

88 In this systematic review and meta-analysis, we evaluated the available evidence on the
89 PK of antituberculosis drugs in diabetic individuals to provide in-depth analysis to guide
90 patient management.

91

92 METHODS

93

94 *Search Strategy*

95 We retrieved all original studies evaluating the effect of DM on the PK of all TB drugs
96 recommended by the WHO for the treatment of drug-sensitive (DS) and drug-resistant TB.
97 We systematically searched major databases including conference abstracts from 1946 to
98 6th of July 2023 using Medical Subject Headings (MeSH) terms (Supplementary Material).
99 We also manually screened the references of included original studies. To identify
100 unpublished studies, <http://clinicaltrials.gov> was searched. This systematic review was
101 conducted in accordance with the PRISMA statement. The protocol was registered at
102 PROSPERO (CRD42022323566).

103

104 **Study Selection**

105 Studies that reported PK of anti-TB medications among DM and non-DM participants were
106 included. No restrictions on language and publication date were applied. General PK
107 studies reporting a subgroup of DM participants were not eligible unless they included
108 detailed PK parameters for DM and non-DM participants. Review articles, letters, case
109 reports and case series with less than five participants were excluded, as were non-human
110 studies.

111

112 **Data Extraction**

113 Two authors screened and retrieved articles according to the eligibility criteria and
114 performed full text review and final article selection. The following variables were
115 extracted: demographics of comparator group(s) and the DM group including age, weight,
116 and sex, study design, DM diagnosis, and DM medications, dose, dosing interval,
117 sampling points, AUC, peak drug concentration (C_{max}), half-life ($t_{1/2}$), time to reach C_{max}
118 (T_{max}), volume of distribution (Vd) and clearance (CL) and were stratified by group. If these
119 data were not reported, we also contacted the authors to request the data.

120

121 **Risk of bias in included studies**

122 In the absence of available tools to assess risk of bias in PK studies, we assessed study
123 quality and risk of bias using the ROBINS-I tool for non-randomised studies of
124 interventions.¹⁴ Any disagreements regarding grading of quality were resolved through
125 discussion with a third author.

126

127 **Analysis**

128 Narrative synthesis of the findings was conducted and reported according to the Synthesis
129 Without Meta-analysis (SWiM) guidelines. Descriptive statistics was used to describe key

130 outcome measures. The pooled mean difference (MD) and 95% confidence interval (CI)
131 was calculated for the main PK parameters of RIF, INH, PZA and ethambutol (ETB),
132 through a random-effects model, when at least data from two studies were available. We
133 compared values between TB patients with and without DM. Data expressed as medians
134 (with interquartile range, IQR) were converted to means and standard deviations (SD).¹⁵
135 The pooling was performed according to an available case analysis scenario. Studies
136 reporting means without SD values, medians without enough data to derive means and
137 those reporting geometric means were excluded, since arithmetic means cannot be
138 computed without raw data and log-transformed data cannot be mixed with untransformed
139 ones in a meta-analysis.¹⁶ To express the amount of heterogeneity and estimate the
140 between-study variance, when at least three studies were available for pooling a prediction
141 interval (PI), was calculated.¹⁷ All calculations were carried out using R software, version
142 4.1.0, 'meta' package.

143

144 **RESULTS**

145 4173 potentially relevant articles were identified. After removing duplicates, 3464 articles
146 were retrieved for initial screening and 49 studies were included for full text review. After
147 reviewing the eligibility criteria, 21 articles were included that assessed the PK of anti-TB
148 medications among TB-DM patients.^{11,18-37} Five included papers presented the same
149 data: in conference abstract³⁸⁻⁴² and then in published form;^{19,25,29,32,39} we included data
150 from the published report. One study was only published as a conference abstract and the
151 authors were not able to share data at the time of this review.⁴³ No relevant unpublished
152 studies were found. The study selection process is recorded in a PRISMA flow diagram
153 (**Figure 1**).

154

155 ***Risk of bias assessment***

156 The risk of bias for each domain across all included studies is given in Supplementary
157 material. While all studies have made a comparative analysis between DM and non-DM
158 population, all had moderate to serious risk of bias in at least one domain. Overall, the
159 existing body of literature examining PK of anti-TB medications among DM population is of
160 medium quality.

161

162 ***Rifampicin (Table 1)***

163 Of the 21 studies, 16 measured RIF plasma concentrations,^{11,18,19,21,23,24,26-32,34-36} majority
164 of which were prospective PK studies except one retrospective study reporting results
165 based on routinely collected data.²⁴

166

167 Out of 16 studies, 7 reported AUC values; three with intensive sampling (> 6 samples)
168^{27,28,34} reporting AUC₀₋₂₄ mg.h/L, three reported AUC₀₋₆ mg.h/L,^{11,29,32} and one reported
169 AUC₀₋₈ mg.h/L.²³ Fifteen measured RIF peak concentrations (C_{max}); mean absolute RIF
170 C_{max} was below the recommended range (above 8 mg/L⁴⁴) in diabetic and non-diabetic
171 groups in the majority of studies, and within the recommended range only in the 3 studies
172 with intensive sampling.^{27,28,34} Eight studies measured T_{max} . In a study using population
173 PK modelling, absorption rate constant (k_a) was significantly increased and the volume of
174 distribution (V_d) was significantly increased in the DM,¹⁹ the authors inferring that the
175 plasma concentrations would therefore be lower in the DM group. Another study found no
176 difference in k_a or V_d between the TB and TB-DM groups, but reduced clearance was
177 observed and V_d was significantly higher in the TB-DM group when V_d was normalized to
178 total body weight.²⁷

179

180 Raised blood glucose was inversely correlated with the rifampicin AUC/ C_{max} in four
181 studies,^{27,29,35,36} whereas three other studies found no association.^{21,28,34} Two studies
182 found that body weight and plasma concentrations were inversely correlated.^{18,29}

183

184 There were significant differences between DM and non-DM groups. Nine studies reported
185 that DM patients had significantly higher BMI or weight^{11,18,21,23,26,27,29,32,35} and nine studies
186 reported the DM group to be older^{11,18,26-28,30,32,34,36}. One study that matched based on sex
187 and age found C_{max} and AUC to be significantly lower and T_{max} significantly longer among
188 DM group compared to non-DM. Eight studies reported DM patients to be on diabetes
189 treatment^{11,18,21,26-30,36}, although no comparative analysis could be done as the majority of
190 patients were receiving anti-diabetic medications.

191

192 Methodology differed between studies. Of the five studies finding a significantly decreased
193 C_{max} in the diabetic group, four performed only a single 2-hour sampling^{18,24,35,36}, with one
194 retrospective study²⁴ and one likely confounded by differences in weight (DM patients
195 weighing more)²⁹.

196

197 DM patients had higher weight and/or BMI and some studies demonstrated a negative
198 association between weight and plasma concentrations. The only study that matched
199 based on weight (within 5 kg)³⁴ found no significant difference of RIF PK between groups.
200 RIF doses used highly differed between studies which may have influenced the results,
201 doses used detailed in Table 1.

202

203 ***Isoniazid (Table 1)***

204 Nine studies assessed isoniazid (INH) PK.^{11,18,22-24,26,28,31,33} Of these, one was based on
205 routinely collected retrospective data,²⁴ four studies used 600 mg dosing 3 times per week
206^{11,23,26,31} and only 1 study sampled intensively.²⁸ Four studies assessed for NAT2 status
207 using different methods.^{22,23,28,33}

208

209 Out of nine studies, four assessed the mean exposure; one AUC₀₋₂₄ mg.h/L,²⁸ two AUC₀₋₆
210 mg.h/L^{11,33} and one AUC₀₋₈ mg.h/L.²³ Four studies examined INH C_{max}^{11,18,26,28} and three
211 studies assessed T_{max}.^{23,33}

212

213 While one study reported concentrations to be negatively correlated with blood glucose,²⁶
214 in two studies INH C_{max}/AUC was not correlated with FBG or HbA1c.^{22,28} In one study INH
215 concentrations were inversely correlated with weight.¹⁸ There were significant differences
216 between groups with the DM group being older and weighing more than non-DM group.

217

218 ***Pyrazinamide (Table 1)***

219 Pyrazinamide PK was reviewed in eight studies,^{11,18,23,25,26,28,31,34} all of which were
220 prospective PK studies. Patients in all studies except two were on 1500 mg PZA dosing,
221 whilst one study used 1600 mg for patients >50 kg and 1200 mg for patients <50 kg²⁸ and
222 other used 20-30 mg/kg.²⁵ Out of eight, four papers reported mean exposure to PZA; two
223 reporting AUC₀₋₂₄ mg.h/L,^{28,34} one AUC₀₋₈ mg.h/L²³ and one AUC₀₋₆ mg.h/L.¹¹ Six studies
224 reported C_{max} and three studies measured T_{max}.

225

226 No correlation between FBG and AUC/C_{max} was observed in two studies^{28,34} whereas one
227 study showed a negative correlation.²⁶ In a population PK modelling study,²⁵ increased
228 apparent clearance was observed in TB-DM patients, most significantly in the group with
229 patients >70 years and AUC₀₋₂₄ mg.h/L was decreased in the DM group >70 years.

230

231 ***Ethambutol (Table 1)***

232 Three included studies assessed the effect of DM on EMB PK.^{18,28,34} Two reported AUC₀₋
233 ₂₄ mg.h/L and T_{max}^{28,34}, all reported C_{max}.

234

235 **Other agents (Table 1)**

236 Two studies assessed the effect of DM on cycloserine,³⁷ linezolid³⁷ and moxifloxacin.²⁰ A
237 retrospective cross-sectional study reviewing the 2 h post-dose in routine practice found
238 that 55% of the samples had below the lower limit of recommended cycloserine plasma
239 concentrations and 17% had low linezolid concentrations.³⁷ DM patients had a lower
240 cycloserine exposure, although this was not statistically significant, and there was no
241 association between linezolid exposure and DM. In a recent retrospective study evaluating
242 moxifloxacin PK, AUC_{0-24h} was shown to be significantly lower in patients with DM
243 compared to age, sex and RIF matched TB patients without DM.²⁰ In line, peak and
244 trough concentrations were also reduced in DM patients. Although the drug absorption,
245 volume of distribution and T_{max} were comparable between TB-DM and TB patients,
246 moxifloxacin clearance was increased in TB-DM patients.

247

248 **Meta-analysis**

249 A quantitative pooling was possible in seven cases, of which four involved RIF. We pooled
250 data from four studies reporting RIF T_{max}.^{27-30,34} Overall, RIF T_{max} was significantly higher
251 in the TB-DM group: MD 0.65 (95% CI, 0.03-1.27) (Figure 2). Two studies were pooled for
252 RIF AUC₀₋₂₄,^{27,30} four for RIF C_{max}^{21,23,27,30} and four for RIF C_{2hr}^{18,26,31,35}, and no
253 statistically significant differences were detected (Figure 2-3). However, RIF C_{2hr} was lower
254 in TB-DM group with a MD of -1.68 (95% CI, -5.41; 2.05). In regard to other first line drugs,
255 we observed no significant differences for INH C_{2hr}, PZA C_{2hr}, PZA T_{max} and ETB T_{max}
256 (supplementary material).

257

258 **DISCUSSION**

259

260 This systematic review provides a comprehensive account of the impact of DM on the PK
261 of anti-TB medications. While the evidence is heterogeneous, according to our analysis,
262 RIF T_{max} is significantly prolonged in patients with DM compared to non-DM patients;
263 however, PI crossed the no-effect threshold, indicating that in future studies opposite
264 results may be determined. Whereas we found no significant differences between DM and
265 non-DM patients for RIF C_{max}, AUC₀₋₂₄ or C_{2hr}, INH C_{2hr}, PZA C_{2hr}, PZA T_{max} and ETB

266 T_{max} . While RIF C_{2hr} was slightly reduced in TB-DM patients, this finding was not
267 statistically significant.

268

269 Diabetes predominantly effects gastric motility via neuropathy.¹² This would be postulated
270 to prolong T_{max} rather than reduce the overall AUC. Our findings of prolonged RIF T_{max}
271 may be a reflection of the impact of DM on gastric motility and delay in drug absorption.
272 However, the efficacy of most of the anti-TB medications is driven by AUC, which is
273 difficult to determine with 1 or 2 sampling timepoints. Therefore, interpretation of studies
274 with limited sampling points should be with caution. Studies with more than one sampling
275 point, ideally with intensive sampling comparing DM vs non-DM population, or limited
276 sampling strategy using population PK modelling will guide our management strategy in
277 this population.

278

279 There is some evidence that PK among DM patients, may have clinical relevance in terms
280 of MIC and culture conversion. In a retrospective study, where all DM patients underwent
281 TDM and dose adjustment accordingly, time to culture conversion improved significantly
282 (average 19 days earlier) among DM patients.⁴⁵ Recently, studies with higher doses of
283 RIF has demonstrated bacteriologically sustained cure in a general TB population.⁴⁶
284 Perhaps these results and the higher RIF strategy have more relevance for the TB-DM
285 population in which we observe more heterogenous plasma concentrations and that
286 reducing the bacterial burden quicker may result in reduced relapse rates.

287

288 We observed high variability in findings and significant heterogeneity among studies.
289 Firstly, there were differences in terms of demographics; age, sex and body weight, DM
290 diagnosis and anti-DM medications. Increased body surface area distribution, delayed
291 drug absorption due to DM related gastroparesis and changes in expression of enzymes
292 involved in metabolism⁴⁷ are major factors that may contribute to altered PK.^{12,48} In most
293 studies, DM patients weighted more than non-DM controls. However, matching weight is
294 unlikely to eliminate potential biases as DM participants continued to receive capped
295 dosing despite weight differences. Screening DM at the time of TB diagnosis may result
296 in some with transient hyperglycaemia being identified as DM. While most of the patients
297 were on anti-diabetic medications, the degree of diabetic control was not provided, limiting
298 our understanding.

299

300 Secondly, PK sampling methodology and drug doses used varied widely across studies.
301 Those with a single 2 hr sampling point assume T_{max} to occur at 2 hrs (C_{max}). Therefore,
302 studies without intensive sampling may not accurately capture the C_{max} . However, it is
303 important to note T_{max} is highly variable for RIF in general. Particularly affecting the
304 isoniazid studies, dosing differed markedly, with 4 out of 9 using 600 mg 3 times/week,
305 which is no longer recommended. Only four out of 9 studies made any assessment of
306 NAT2 acetylator status which is a key variable in isoniazid PK likely to confound results.⁴⁹

307

308 We identified another systematic review assessing the impact of DM on the PK of
309 rifampicin among TB patients⁵⁰. The review included studies published up until September
310 2020 and identified seven studies from which pooled estimates were calculated. The same
311 authors updated their systematic review including studies with C_{max} at 2hr,⁵¹ and identified
312 17 studies reporting RIF plasma concentrations.

313

314 Our study has limitations. Firstly, we identified a limited number of PK studies despite a
315 comprehensive literature search. Secondly, due to studies reporting geometric means we
316 were unable to pool data from those reporting AUC 0-24. Finally, we did not include
317 general PK studies reporting on TB-DM patients as a subgroup.

318

319 Given the association observed between dose adjustment and clinical improvement, dose
320 adjustment based on TDM may be beneficial in this patient population. We recognise that
321 in most global settings TDM is not easily available. Until more simplified and cost-effective
322 tests are easily available,⁵² the alternative would be to empirically increase drug doses in
323 all individuals with DM. While TB drug exposures in diabetes is mixed, given RIF has a
324 wide therapeutic window⁵³ and successful treatment outcome depends on sufficient drug
325 exposure, we recommend considering a higher dose limit for patients with DM; instead of
326 capped dosing, using 10mg/kg to be able to correct for larger bodyweight of patients with
327 DM. This is also a group that should be prioritised in ongoing studies addressing
328 empirically increasing doses of TB medications. In order to achieve definitive answers for
329 PK in DM population, we recommend important considerations as in **Table 2**.

330

331 **Acknowledgements**

332 This work was supported by the Chief Scientist Office (CAF/20/03) and British Infection
333 Association (Grant/2022/SPG/MC) received by MC.

334

335 **Author contributions**

336 MC conceptualized the scope of the review, led the systematic review, literature search,
337 data collection and wrote the first and subsequent drafts of the manuscript. AS involved in
338 creating the table from selected papers. AEM performed the meta-analysis on selected
339 papers. All authors contributed to the final version of the manuscript and approved it for
340 publication.

341

342 **Declaration of Interests**

343 No conflict of interests reported.

344

345 **Figures and tables:**

346 Figure 1: Flowchart describing study selection

347 Figure 2: Meta-analysis of Rifampicin (RIF AUC₀₋₂₄ and RIF T_{max})

348 Figure 3: Meta-analysis of Rifampicin (RIF C_{max} and C_{2hr})

349 Table 1: Summary of included studies

350 Table 2: Recommendations for future research

351 **References:**


- 352 1. WHO. World Health Organization, Global tuberculosis report 2022
353 . 2022. <https://www.who.int/publications/i/item/9789240061729>.
- 354 2. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of
355 diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; **138**:
356 271-81.
- 357 3. Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active
358 tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with
359 tuberculosis. *Lancet Glob Health* 2019; **7**(4): e448-e60.
- 360 4. Koesoemadinata RC, McAllister SM, Soetedjo NNM, et al. Latent TB infection and
361 pulmonary TB disease among patients with diabetes mellitus in Bandung, Indonesia.
362 *Trans R Soc Trop Med Hyg* 2017; **111**(2): 81-9.
- 363 5. Foe-Essomba JR, Kenmoe S, Tchatchouang S, et al. Diabetes mellitus and
364 tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies
365 comparable for confounders. *PLoS One* 2021; **16**(12): e0261246.
- 366 6. Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis
367 treatment outcomes: a systematic review. *BMC Med* 2011; **9**: 81.
- 368 7. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes
369 on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *Int*
370 *J Tuberc Lung Dis* 2019; **23**(7): 783-96.
- 371 8. Dong Z, Shi J, Dorhoi A, et al. Hemostasis and Lipoprotein Indices Signify
372 Exacerbated Lung Injury in TB With Diabetes Comorbidity. *Chest* 2018; **153**(5): 1187-200.
- 373 9. Salindri AD, Kipiani M, Kempker RR, et al. Diabetes Reduces the Rate of Sputum
374 Culture Conversion in Patients With Newly Diagnosed Multidrug-Resistant Tuberculosis.
375 *Open Forum Infect Dis* 2016; **3**(3): ofw126.
- 376 10. Zheng X, Bao Z, Forsman LD, et al. Drug Exposure and Minimum Inhibitory
377 Concentration Predict Pulmonary Tuberculosis Treatment Response. *Clin Infect Dis* 2021;
378 **73**(9): e3520-e8.
- 379 11. Alfarisi O, Mave V, Gaikwad S, et al. Effect of Diabetes Mellitus on the
380 Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment. *Antimicrob Agents*
381 *Chemother* 2018; **62**(11): 11.
- 382 12. Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on
383 pharmacokinetic and pharmacodynamic properties of drugs. *Clin Pharmacokinet* 2012;
384 **51**(8): 481-99.
- 385 13. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical
386 and molecular perspective. *Antimicrob Agents Chemother* 2002; **46**(2): 267-74.
- 387 14. Gafar F, Wasmann RE, McIlhleron HM, et al. Global estimates and determinants of
388 antituberculosis drug pharmacokinetics in children and adolescents: a systematic review
389 and individual patient data meta-analysis. *Eur Respir J* 2023; **61**(3).
- 390 15. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
391 deviation from the sample size, median, range and/or interquartile range. *BMC Med Res*
392 *Methodol* 2014; **14**: 135.
- 393 16. Deeks JJ HJ, Altman DG Chapter 10: Analysing data and undertaking meta-
394 analyses. Cochrane Handbook for Systematic Reviews of Interventions version 6.4
395 (updated August 2023). Cochrane, 2023. .
- 396 17. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses.
397 *BMJ* 2011; **342**: d549.
- 398 18. Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin
399 are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. *Antimicrob*
400 *Agents Chemother* 2013; **57**(11): 5740-2.

- 401 19. Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the
402 population pharmacokinetics of rifampin in tuberculosis patients. *Tuberculosis (Edinb)*
403 2015; **95**(1): 54-9.
- 404 20. Dekkers BGJ, Bolhuis MS, Beek LT, et al. Reduced moxifloxacin exposure in
405 patients with tuberculosis and diabetes. *European Respiratory Journal* 2019; **54**(3) (no
406 pagination).
- 407 21. Fonseca AAD, Pinto ACG, Paixao TPD, Alberio CAA, Vieira JLF. Can diabetes
408 mellitus modify the plasma concentrations of rifampicin in patients under treatment for
409 tuberculosis? *Brazilian Journal of Infectious Diseases* 2020; **24**(4): 352-5.
- 410 22. Galvao FES, Fonseca AAD, Pinto ACG, da Paixao TP, Alberio CAA, Vieira JLF. No
411 significant influence of diabetic mellitus on isoniazid plasma levels in patients under
412 treatment for tuberculosis. *Infectious Diseases* 2020; **52**(8): 577-80.
- 413 23. Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of
414 thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
415 *Int J Tuberc Lung Dis* 2016; **20**(9): 1236-41.
- 416 24. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow
417 response to tuberculosis treatment in a state control program, Virginia, USA. *Emerg Infect*
418 *Dis* 2010; **16**(10): 1546-53.
- 419 25. Kim R, Jayanti RP, Kim HK, et al. Development of a population pharmacokinetic
420 model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes
421 mellitus on clearance. *Front Pharmacol* 2023; **14** (no pagination): 1116226.
- 422 26. Kumar AK, Chandrasekaran V, Kannan T, et al. Anti-tuberculosis drug
423 concentrations in tuberculosis patients with and without diabetes mellitus. *Eur J Clin*
424 *Pharmacol* 2017; **73**(1): 65-70.
- 425 27. Medellin-Garibay SE, Cortez-Espinosa N, Milan-Segovia RC, et al. Clinical
426 Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus:
427 Association with Biochemical and Immunological Parameters. *Antimicrob Agents*
428 *Chemother* 2015; **59**(12): 7707-14.
- 429 28. Mtabho CM, Semvua HH, van den Boogaard J, et al. Effect of diabetes mellitus on
430 TB drug concentrations in Tanzanian patients. *J Antimicrob Chemother* 2019; **74**(12):
431 3537-45.
- 432 29. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly
433 reduced in patients with tuberculosis and type 2 diabetes. *Clin Infect Dis* 2006; **43**(7): 848-
434 54.
- 435 30. Perea-Jacobo R, Muniz-Salazar R, Laniado-Laborin R, Cabello-Pasini A, Zenteno-
436 Cuevas R, Ochoa-Teran A. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus
437 patients: a pilot study from Baja California, Mexico. *Int J Tuberc Lung Dis* 2019; **23**(9):
438 1012-6.
- 439 31. Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic rifampicin
440 concentration is associated with unfavorable tuberculosis treatment outcomes. *Clin Infect*
441 *Dis* 2020; **70**(7): 1463-70.
- 442 32. Requena-Mendez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in
443 Peruvian tuberculosis patients with and without comorbid diabetes or HIV. *Antimicrob*
444 *Agents Chemother* 2012; **56**(5): 2357-63.
- 445 33. Requena-Mendez A, Davies G, Waterhouse D, et al. Effects of dosage,
446 comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.
447 *Antimicrob Agents Chemother* 2014; **58**(12): 7164-70.
- 448 34. Ruslami R, Nijland HM, Adhiarta IG, et al. Pharmacokinetics of antituberculosis
449 drugs in pulmonary tuberculosis patients with type 2 diabetes. *Antimicrob Agents*
450 *Chemother* 2010; **54**(3): 1068-74.
- 451 35. Samuel Gideon George P, Saranya P. Effect of patient-specific variables on
452 rifampicin peak serum concentration. *Drug Invention Today* 2018; **10**(3): 290-6.

- 453 36. Saranya P, Parthasarathy V, Hariprasad B, Shobha Rani H. Effect of diabetes
454 mellitus on rifampicin peak serum concentration. *International Journal of Pharmacy and*
455 *Pharmaceutical Sciences* 2016; **8(10)**: 149-52.
- 456 37. Zhu H, Guo SC, Liu ZQ, et al. Therapeutic drug monitoring of cycloserine and
457 linezolid during anti-tuberculosis treatment in Beijing, China. *Int J Tuberc Lung Dis* 2018;
458 **22(8)**: 931-6.
- 459 38. Chang MJ, Shin W, Song J, et al. The pharmacokinetics of four standard anti-
460 tuberculosis drugs in tuberculosis patients with diabetes mellitus. *Respirology* 2009; **3**):
461 A231.
- 462 39. Mtabho C, Semvua H, Kibiki G, Tostmann A, Aarnoutse R. The effect of diabetes
463 mellitus on the pharmacokinetics of tuberculosis drugs in Tanzanian patients. *Tropical*
464 *Medicine and International Health* 2015; **1**): 23.
- 465 40. Nijland H, Ruslami R, Stalenhoef J, et al. Exposure to rifampicin is reduced by 53%
466 in tuberculosis patients with Diabetes Mellitus. *Br J Clin Pharmacol* 2006; **62(6)**: 730-.
- 467 41. Mendez AR, Moore DAJ, Davies G. Improving management of TB in the tropics
468 Rifampicin pharmacokinetics in peruvian tuberculosis patients with and without co-morbid
469 diabetes or HIV. *Tropical Medicine and International Health* 2011; **1**): 62.
- 470 42. Kim R, Jayanti R, Jang T, et al. Development of Population Pharm Aco Kin Etics
471 Model of Pyrazinamide and Optimal Dose Recommendation for Elderly with Diabetes
472 Mellitus in Korean Tuberculosis Patients. *Clinical Pharmacology and Therapeutics* 2023;
473 **113(Supplement 1)(S1)**: S94.
- 474 43. Christopher DJ, Jedidiah D, Isaac B, Mathew B, Winston B. Anti-tubercular drug
475 concentrations in pulmonary tuberculosis patients-diabetic vs non-diabetic groups.
476 *European Respiratory Journal Conference: 29th International Congress of the European*
477 *Respiratory Society, ERS Madrid Spain 2019*; **54(Supplement 63)**.
- 478 44. Peloquin CA, Velasquez GE, Lecca L, et al. Pharmacokinetic Evidence from the
479 HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. *Antimicrob Agents*
480 *Chemother* 2017; **61(8)**.
- 481 45. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for
482 diabetes related tuberculosis associate with hastened sputum microbiological clearance in
483 Virginia, USA. *BMC Infect Dis* 2017; **17(1)**: 125.
- 484 46. Paton NI, Cousins C, Suresh C, et al. Treatment Strategy for Rifampin-Susceptible
485 Tuberculosis. *N Engl J Med* 2023; **388(10)**: 873-87.
- 486 47. Kuppusamy UR, Indran M, Rokiah P. Glycaemic control in relation to xanthine
487 oxidase and antioxidant indices in Malaysian Type 2 diabetes patients. *Diabet Med* 2005;
488 **22(10)**: 1343-6.
- 489 48. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on
490 pharmacokinetics and pharmacodynamics in humans. *Clin Pharmacokinet* 1991; **20(6)**:
491 477-90.
- 492 49. Hong BL, D'Cunha R, Li P, et al. A Systematic Review and Meta-analysis of
493 Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis. *Clin*
494 *Ther* 2020; **42(11)**: e220-e41.
- 495 50. Metwally AS, El-Sheikh SMA, Galal AAA. The impact of diabetes mellitus on the
496 pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and
497 meta-analysis study. *Diabetes Metab Syndr* 2022; **16(2)**: 102410.
- 498 51. El-Sheikh SMA, Metwally AS, Galal AAA. Impact of diabetes mellitus on rifampicin's
499 plasma concentration and bioavailability in patients with tuberculosis: A systematic review
500 and meta-analysis study. *Therapie* 2023; **78(3)**: 313-24.
- 501 52. Xie YL, Modi N, Handler D, et al. Simplified urine-based method to detect rifampin
502 underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.
503 *Antimicrob Agents Chemother* 2023; **67(11)**: e0093223.

504 53. Akkerman OW, Dijkwel RDC, Kerstjens HAM, et al. Isoniazid and rifampicin
505 exposure during treatment in drug-susceptible TB. *Int J Tuberc Lung Dis* 2023; **27**(10):
506 772-7.
507
508
509

Figure 1. Flowchart describing study selection



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.